A human immunodeficiency virus type 1 Env-granulocyte-macrophage colony-stimulating factor fusion protein enhances the cellular immune response to Env in a vaccinia virus-based vaccine

Journal of General Virology

Volumn 80, Issue 1, 1999, Pages 217-223

  Rodríguez, Dolores ^a   Rodríguez, Juan Ramón ^a   Llorente, Mercedes ^a   Vázquez, Isabel ^a   Lucas, Pilar ^a   Esteban, Mariano ^a   Martínez A, Carlos ^a   Del Real, Gustavo ^a  

^a CENTRO NACIONAL DE BIOTECNOLOGÍA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; GLYCOPROTEIN GP 120; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HYBRID PROTEIN; VACCINIA VACCINE; VIRUS ANTIGEN; VIRUS ENVELOPE PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY TITER; ARTICLE; CELLULAR IMMUNITY; FEMALE; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOGENICITY; INTRAPERITONEAL DRUG ADMINISTRATION; NONHUMAN; PRIORITY JOURNAL; VACCINIA; VACCINIA VIRUS; VIRUS IMMUNITY; VIRUS RECOMBINANT;

ANIMALIA; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; PAN (APE); VACCINIA; VACCINIA VIRUS;

EID: 18244415747     PISSN: 00221317     EISSN: None     Source Type: Journal    
DOI: 10.1099/0022-1317-80-1-217     Document Type: Article

References (30)

1. Ahlers, J. D., Dunlop, N., Alling, D. W., Nara, P. L. & Berzofsky, J. A. (1997). Cytokine-in-adjuvant steering of the immune response phenotype to HIV-1 vaccine constructs. Journal of Immunology 158, 3947-3958.
2. Chakrabarty, S., Robert-Guroff, M., Wong-Stall, F., Gallo, R. C. & Moss, B. (1986). Expression of the HTLV-III envelope gene by a recombinant vaccinia virus. Nature 320, 535-537.
3. Cooney, E. L., McElrath, J. M., Corey, L., Hu, S.-L., Collier, A. C., Arditti, D., Hoffman, M., Coombs, R. W., Smith, G. E. & Greenberg, P. D. (1993). Enhanced immunity to human immunodeficiency virus (HIV) envelope elicited by a combined vaccine regime consisting of priming with a vaccinia recombinant expressing HIV envelope and boosting with gp160 protein. Proceedings of the National Academy of Sciences, USA 90, 1882-1886.
4. Disis, M. L., Bernhard, H., Shiota, F. M., Hand, S. L., Gralow, J. R., Huseby, E. S., Gillis, S. & Cheever, M. A. (1996). Granulocyte-macrophage colony-stimulating factor: an effective adjuvant for protein and peptide-based vaccines. Blood 88, 202-210.
5. Dranoff, G., Jaffee, E., Lazenby, A., Golumbek, P., Levitsky, H., Brose, K., Jackson, V., Hamada, H., Pardoll, D. & Mulligan, R. C. (1993). Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proceedings of the National Academy of Sciences, USA 90, 3539-3543.
6. Earl, P. L., Robert-Guroff, M., Matthews, T. J., Krohn, K., London, W. T. & Moss, B. (1989). Isolate-and group-specific immune responses to the envelope protein of human immunodeficiency virus induced by a live recombinant vaccinia virus in macaques. AIDS Research and Human Retroviruses 5, 23-32.
7. Egan, M. A., Pavlat, W. A., Tartaglia, J., Paoletti, E., Weinhold, K. J., Clements, M. L. & Siliciano, R. F. (1995). Induction of human immunodeficiency virus type 1 (HIV-1)-specific cytolytic T lymphocyte responses in seronegative adults by a nonreplicating, host-range-restricted canarypox vector (ALVAC) carrying the HIV-1MN env gene. Journal of Infectious Diseases 171, 1623-1627.
8. Ellem, K. A., O'Rourke, M. G., Johnson, G. R., Parry, G., Misko, I. S., Schmidt, C. W., Parsons, P. G., Burrows, S. R., Cross, S., Fell, A., Li, C. L., Bell, J. R., Dubois, P. J., Moss, D. J., Good, M. F., Kelso, A., Cohen, L. K., Dranoff, G. & Mulligan, R. C. (1997). A case report: immune responses and clinical course of the first human use of granulocyte/macrophage-colony-stimulating-factor-transduced autologous melanoma cells for immunotherapy. Cancer Immunology Immunotherapy 44, 10-20.
9. Fenner, F., Henderson, D. A., Arita, I., Jezek, Z. & Ladnyi, I. D. (1988). Smallpox and Its Eradication. Geneva: World Health Organization.
10. Fleury, B., Janvier, G., Pialoux, G., Buseyne, F., Robertson, M. N., Tartaglia, J., Paoletti, E., Kieny, M. P., Excler, J. L. & Riviere, Y. (1996). Memory cytotoxic T lymphocyte responses in human immunodeficiency virus type 1 (HIV-1)-seronegative volunteers immunized with a recombinant canarypox expressing gp160 of HIV-1 and boosted with a recombinant gp160. Journal of Infectious Diseases 174, 734-738.
11. Goudsmit, J., Back, N. K. T. & Nara, P. L. (1991). Genomic diversity and antigenic variation of HIV-1: links between pathogenesis, epidemiology and vaccine development. FASEB Journal 5, 2427-2436.
12. Gough, N. M., Gough, J., Metcalf, D., Kelso, A., Grail, D., Nicola, N. A., Burgess, A. W. & Dunn, A. R. (1984). Molecular cloning of cDNA encoding a murine haematopoietic growth regulator, granulocyte-macrophage colony stimulating factor. Nature 309, 763-767.
13. Grabstein, K., Mochizuki, D., Kronheim, S., Price, V., Cosman, D., Urdal, D., Gillis, S. & Conlon, P. (1986). Regulation of antibody production in vitro by granulocyte-macrophage colony stimulating factor. Journal of Molecular and Cellular Immunology 2, 199-207.
14. Graham, B. S., Matthews, T. J., Belshe, R. B., Clements, M. L., Dolin, R., Wright, P. F., Gorse, G. J., Schwartz, D. H., Keefer, M. C., Bolognesi, D. P., Corey, L., Stablein, D. M., Esterliz, J. R., Hu, S.-L., Smith, G. E., Fast, P. E. & Koff, W. C. (1993). Augmentation of human immunodeficiency virus type 1 neutralizing antibody by priming with gp160 recombinant vaccinia and boosting with rgp160 in vaccinia-naive adults. The NIAD AIDS Vaccine Clinical Trials Network. Journal of Infectious Diseases 167, 533-537.
15. Ho, D. D., Sarngadharan, M. G., Hirsch, M. S., Schooley, R. T., Rota, T. R., Kennedy, R. C., Chanh, T. C. & Sato, V. L. (1987). Human immunodeficiency virus neutralizing antibodies recognize several conserved domains on the envelope glycoproteins. Journal of Virology 61, 2024-2028.
16. Hu, S. L., Kosowski, S. G. & Dalrymple, J. M. (1986). Expression of AIDS virus envelope gene in recombinant vaccinia viruses. Nature 320, 537-539.
17. Kim, J. J., Ayyavoo, V., Bagarazzi, M. L., Chattergoon, M. A., Dang, K., Wang, B., Boyer, J. D. & Weiner, D. B. (1997). In vivo engineering of a cellular immune response by coadministration of IL-12 expression vector with a DNA immunogen. Journal of Immunology 158, 816-826.
18. Luzuriaga, K. & Sullivan, J. L. (1993). HIV-1 specific CTL in long-term survivors of vertical infection. Journal of Cellular Biochemistry Supplement 17E, 98.
19. McElrath, M. J., Corey, L., Berger, D., Hoffman, M. C., Klucking, S., Dragavon, J., Peterson, R. & Greenberg, P. D. (1994). Immune responses elicited by recombinant vaccinia-human immunodeficiency virus (HIV) envelope and HIV envelope proteins: analysis of the durability of responses and effect of repeated boosting. Journal of Infectious Diseases 169, 41-47.
20. Metcalf, D. (1986). The molecular biology and functions of the granulocyte-macrophage colony-stimulating factors. Blood 67, 257-267.
21. + T cells using an ELISPOT assay. Journal of Immunological Methods 181, 45-54.
22. Morrissey, P. J., Bressler, L., Park, L. S., Alpert, A. & Gillis, S. (1987). Granulocyte-macrophage colony-stimulating factor augments the primary antibody response by enhancing the function of antigen-presenting cells. Journal of Immunology 139, 1113-1119.
23. Moss, B. (1996). Genetically engineered poxviruses for recombinant gene expression, vaccination, and safety. Proceedings of the National Academy of Sciences, USA 93, 11341-11348.
24. Paoletti, E. (1996). Applications of poxvirus vectors to vaccination: an update. Proceedings of the National Academy of Sciences, USA 93, 11349-11353.
25. Pialoux, G., Excler, J.-L., Riviere, Y., Gonzalez-Canali, G., Feuillie, V., Coulaud, P., Gluckman, J.-C., Matthews, T. J., Meignier, B., Kieny, M.-P., Gonnet, P., Diaz, I., Meric, C., Paoletti, E., Tartaglia, J., Salomon, H. & Plotkin, S. (1995). A prime-boost approach to HIV preventive vaccine using a recombinant canarypox virus expressing glycoprotein 160 (MN) followed by a recombinant glycoprotein 160 (MN/LAI). AIDS Research and Human Retroviruses 11, 373-381.
26. Rodríguez, D., Rodríguez, J. R., Rodríguez, J. F., Trauber, D. & Esteban, M. (1989). Highly attenuated vaccinia virus mutants for the generation of safe recombinant viruses. Proceedings of the National Academy of Sciences, USA 86, 1287-1291.
27. Sallusto, F. & Lanzavecchia, A. (1994). Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte-macrophage colony-stimulating factor plus interleukin-4 and down-regulated by tumor necrosis factor-α. Journal of Experimental Medicine 179, 1109-1118.
28. Smith, P. D., Lamerson, C. L., Wong, H. L., Wahl, L. M. & Wahl, S. M. (1990). Granulocyte-macrophage colony-stimulating factor stimulates human monocyte accessory cell function. Journal of Immunology 144, 3829-3834.
29. Steinman, R. (1991). The dendritic cell system and its role in immunogenicity. Annual Review of Immunology 9, 271-296.
30. Tao, M. H. & Levy, R. (1993). Idiotype/granulocyte-macrophage colony-stimulating factor fusion protein as a vaccine for B-cell lymphoma. Nature 362, 755-758.